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Abstract Glycosylphosphatidylinositol anchoring is a type
of post-translational modification that allows proteins to be
presented on the exterior side of the cell membrane. Puri-
fied glycosylphosphatidylinositol-anchored protein can
spontaneously re-insert into lipid bilayer membranes in a
process termed Molecular Painting. Here, we demonstrate
the possibility of inserting purified, recombinant CD59 into
virus particles produced from a murine retroviral producer
cell line. CD59 is a regulator of the complement system
that helps protect healthy cells from the lytic activity of the
complement cascade. In this study, we could show that
Molecular Painting confers protection from complement
activity upon murine retroviral vector particles. Indeed,
increased infectivity of CD59-modified virus particles was
observed upon challenge with human serum, indicating that
Molecular Painting is suitable for modulating the immune
system in gene therapy or vaccination applications.
Keywords Molecular Painting  Protein engineering 
Gene therapy  Vaccination  Viral vectors  Complement 
CD59
Abbreviations
CSR Cellular survival rates
GPI Glycosylphosphatidylinositol
GSS GPI signalling sequence
MP Molecular Painting
VPF Virus protection factors
Introduction
Approximately 0.5 % of eukaryotic protein species carry a
glycosylphosphatidylinositol (GPI) anchor [8]. Biochemi-
cally, the GPI anchor is characterized by an ethanolamine
residue connecting the anchor to the C terminus of a pro-
tein, followed by a characteristic stretch of carbohydrate
elements, mainly mannose residues [14] which in turn is
connected to the phosphoinositol moiety with 2–3 lipid
residues which are finally anchored in the outer leaflet of
the plasma membrane [6]. Functionally, GPI-anchored
proteins are diverse: they contribute to the regulation of the
immune system (CD55, CD59), have enzymatic activities
(alkaline phosphatase) or play roles in signal transduction
(Thy-1) [13]. GPI anchoring is achieved by the transfer of
preformed anchor structures onto proteins at the inner
membranes of the endoplasmatic reticulum (ER) by the
transamidase (TA) enzyme complex. Generation of the
anchor requires the concerted activity of more than 20
enzymes [12]. GPI-anchored proteins may be released from
cell membranes and shed into the surrounding media by
different mechanisms: either as part of membrane-bound
vesicles, such as exosomes, but also in forms excluding
lipids both with absent or intact anchoring structures [1, 17,
20]. An interesting property of GPI-anchored proteins is
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that they are capable of re-inserting into lipid bilayer
membranes [3–5, 7, 21, 22, 26, 29, 31–35]. This was
described for the first time in 1984 for cell membranes
under the term cell painting [21]. In 2008, we extended the
system to include enveloped viral particles, originally of
retroviral origin [29]. In 2013, also Influenza and her-
pesvirus particles were shown to be susceptible to Molec-
ular Painting (MP) [26]. Infectivity of the virus is not
necessarily inhibited by the modification itself [26, 29];
however, all post-exit incubation steps will reduce the viral
half-life as a simple consequence of handling and exposure
to ambient or elevated temperatures. Proteins may be
converted into recombinant GPI-anchored proteins by
introducing a C-terminal GPI signalling sequence (GSS) in
addition to an N-terminal signal peptide (SP) [15, 16, 27,
28]. While the SP directs the nascent protein towards the
ER, the GSS is recognized by the TA complex and transfer
of the preformed GPI anchor can occur [28, 30]. In such a
manner, for example, green fluorescent protein (GFP) [19,
26], CD4 [3] and interleukin-2 (IL-2) [15] have been
converted into GPI-anchored proteins. Recently, artificially
GPI-anchored proteins have been used for biomedical
applications in vivo [32–34]. In contrast, CD59 (alterna-
tively called protectin) is a naturally occurring GPI-an-
chored protein with functions in the regulation of
complement activity. The complement system constitutes a
part of the innate immune system that attacks pathogens
upon triggering by various stimuli, mainly the generation
of antigen–antibody complexes, but also a range of anti-
body-independent signals such as carbohydrate residues or
different pathogen-derived proteins [11, 39, 41]. Enveloped
viral particles are susceptible to inactivation by the com-
plement [2, 11, 39–41], but may also subvert the system to
promote acute or persistent infections [9, 11, 18]. Three
different pathways of complement activity are described:
the classical, alternative and lectin pathways [23]. These
pathways show a considerable overlap and lead to the same
effector mechanism. The initiator protein of the classical
pathway, C1q, interacts with more than 100 different pro-
teins, including a range of viral envelope glycoproteins
[41]. Additionally, the main initiator protein of the lectin
pathway, mannose-binding lectin MBL, also binds to viral
surface markers, e.g. of human immunodeficiency virus
type 1 (HIV-1) [41]. From a biochemical viewpoint, pro-
teolytic cascades are initiated (for a recent, comprehensive
review see [23, 24]) leading to membrane deposition of
enzymatically active protein complexes (‘‘convertases’’)
and the formation of soluble pro-inflammatory intermedi-
ates, termed anaphylatoxins. Effector mechanisms of the
complement system include the generation of said ana-
phylatoxins and the formation of lytic pores in lipid
membranes through formation of the membrane attack
complex (MAC). Additionally, opsonization of pathogens
allows for a more efficient recognition, uptake and pro-
cessing of antigens by professional antigen-presenting
cells. A tight regulation of the complement system is
necessary to avoid prolonged or unwarranted activation. A
whole range of regulatory molecules (both soluble and
membrane-bound), including CD46, CD55 and CD59, are
involved in controlling the complement system. CD59
inhibits formation of the MAC by preventing assembly of
sufficient C8 and C9 late complement proteins [10]. As a
means of immune evasion, lentiviral particles include
complement regulatory proteins into their envelope when
budding from the cell, thus protecting them from the
complement system [36, 37]. Artificial display of CD59
on viral particles after transfection of murine virus-pro-
ducing cell lines also induced protection of viral particles
from the complement [2, 38]. In this study, we proposed
to protect retroviral vector particles produced from a non-
human source, i.e. mouse-derived PALSG/S cells [2],
from the human complement system by means of MP
(rather than transfection) to provide proof-of-principle that
functional surface engineering of vectors via MP may be
employed for fine-tuning of viral vector properties, e.g.




CrFK, HeLa and NIH3T3 cells were acquired from ATCC
stocks (Accession numbers CCL94, CCL-2 and CRL-1658,
respectively). The generation of the expression plasmids
coding for CD59his (pCD59hisneo) and the respective
expressing cell lines has been described previously [29].
The murine leukaemia virus (MLV)-based vector particles
pseudotyped with 4070A amphotropic Env were produced
from the stable murine producer cell line PALSG/S [2]
based on the murine fibroblast cell line NIH3T3. All cells
were cultured in DMEM supplemented with 10 % foetal
calf serum (FCS, purchased from BioChroma). Cells
transfected with pCD59hisneo were kept under selection in
400 lg/ml G418 (Sigma-Aldrich). Human serum was
either purchased in lyophilized form (Sigma-Aldrich) or
prepared from healthy human donors. Preparation of serum
and separation from cellular proteins were carried out using
BD VacutainerR Rapid Serum Tubes (Becton–Dickinson).
In brief, after adding the whole blood to the tubes, blood
rested for 10 min at room temperature and was centrifuged
for 10 min at 15009g. The serum was removed from the
top of the tubes and stored in aliquots at -80 C until use.
In both cases, heat inactivation was carried out at 56 C for
30 min.
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Virus Harvesting
PALSG/S cells were cultured in DMEM (Life Technolo-
gies) containing 10 % FCS (BioChroma). 72 h prior to
harvesting of the viral supernatants, cells were transferred
into serum-free DMEM. Supernatants were centrifuged for
10 min at 23009g before filtration through a 0.45-lm
syringe filter. Finally, supernatants were subjected to
ultracentrifugation in a Beckman ultracentrifuge using an
SW32TI rotor at 54,0009g (at average radius) for 2 h at
4 C. The supernatants were discarded, and the pellets
were resuspended in DMEM and stored at -80 C until
further use.
Protein Purification
A fast protein liquid chromatography (FPLC) device
(A¨ktaPrime Plus, GE HealthCare) using ready-made
immobilized metal affinity chromatography (IMAC) col-
umns (HisTrap FF crude, GE Healthcare) was employed
for protein purification. Cells were washed in PBS and
scraped into PBS. After collecting cells by centrifugation,
sample application buffer (SAB, containing 50 mM Tris–
HCl, 50 mM NaCl, 35 mM imidazole and 1 % (w/v)
octylglucoside (OG), pH 7.4) was added. During the FPLC
procedure, wash buffer (WB, containing 50 mM Tris–HCl,
50 mM NaCl, 35 mM imidazole, pH 7.4) was used and
attached proteins were eluted through a continuous gradi-
ent ending in a final concentration of 100 % elution buffer
(EB, containing 50 mM Tris–HCl, 50 mM NaCl, 600 mM
Imidazole, pH 7.4). Following purification, elution frac-
tions were analysed by UV spectrometry and
immunoblotting. Positive fractions were collected for fur-
ther concentration using ultrafiltration columns (Vivaspin
20 Turbo, Sartorius Stedim, molecular weight cut-off 10
kD) and washed twice in 10 ml protein storage buffer
(50 mM Tris–HCl, 50 mM NaCl, pH 7.4), then stored at
-20 C until further use. Total protein content of the
preparations was determined by a modified Lowry assay
(BioRad Protein DC kit, according to manufacturer’s
instructions). The presence of proteins of interest was
confirmed by immunoblotting.
Immunoblots
Samples were subjected to SDS-PAGE using 10 % gels
and a Laemmli buffer system. Proteins were electro-
transferred onto PVDF membranes (GE Healthcare) and
incubated overnight in blocking buffer (4 % milk powder
w/v; 1 % bovine serum albumin in Tris-buffered saline
containing 0.1 % Tween-20). Primary antibodies were used
in 1:2000 dilutions (for CD59). Antibodies directed against
CD59 were purchased from AbD Serotec. Rat anti-MLV
capsid and envelope antibodies were purified by Biomedica
(Vienna). HRP-labelled anti-murine and anti-rat secondary
antibodies (DakoCytomation) were used in dilutions of
1:5000 and 1:10,000, respectively. ECL detection kits (GE
Healthcare) were used for generating signals, which were
developed and recorded using an AGFA Curix 60 devel-
oper and Hyperfilm ECL (GE Healthcare).
Cellular Serum Response
HeLa, CrFK, CrFK-CD59his and PALSG/S cells were
seeded in triplicate at the densities of 104 cells per well in
96-well plates. 24 h later, cells were treated with DMEM
containing 50 % active human serum or 50 % inactivated
human serum. After 24 h of incubation, the cells were
trypsinized and 50 ll of the cell suspension was used for
manually counting in a counting chamber (MEGUMED
Diagnostik GmbH, Germany).
Molecular Painting
MP reactions were set up in a total volume of 500 ll. The
final concentration of CD59his in MP reactions was 35 ng/
ll. After incubation of samples for 120 min at 37 C under
constant shaking, non-associated protein was removed by
ultracentrifugation as described for the virus harvesting
earlier. Samples were resuspended in 200 ll DMEM.
Serum Treatment and Infections
For infection, HeLa cells were seeded in 6-well plates at a
density of 1.59106 cells per well 24 h prior to infections.
After MP, 200 ll of painted virus was divided in half and
mixed with either 400 ll active human serum or heat-in-
activated human serum. After 1-h incubation at 37 C, 5 %
CO2 under constant agitation samples were added dropwise
onto seeded HeLa cells with additional hexadimethrine
bromide (Sigma-Aldrich) yielding a final concentration of
8 lg/ml to overcome charge repulsion of virus and cell
membranes. After 30-min incubation, 2 ml of DMEM
?10 % FBS and additionally 20 ll hexadimethrine bro-
mide were added dropwise onto HeLa cells (see Sect. 2.9).
The cells were incubated at 37 C, 5 % CO2 until flow
cytometry analysis was carried out.
Flow Cytometry
72 h post infection, cells were washed in PBS once before
being removed from the plates by trypsin. Samples were
collected by centrifugation for 5 min at 2009g, washed in
PBS and centrifuged as described previously. Finally, the
cells were fixed using 4 % formalin in PBS, filtered and
analysed on a BD cytometer using CellQuest software.
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Calculations and Statistical Analysis
Cellular survival rates (CSR, Fig. 3) were calculated as the
number of cells in the samples treated with active serum
multiplied with 100, then divided by the number of cells in
the samples treated with inactivated serum. The virus
protection factor (VPF, Fig. 4) indicates to what extent a
treatment (i.e. MP with CD59his) allows the virus to better
withstand serum complement activity. VPF is calculated as
the ratio of the relative virus survival compared to a ref-
erence (i.e. non-treated). The relative virus survival is
calculated in a similar manner to the CSR: as the per-
centage of infected cells (showing green fluorescence)
incubated with virus samples treated with active serum
multiplied with 100, then divided by the percentage of
infected cells incubated with samples treated with inacti-
vated serum. Student’s t test (two-sided, paired) was used
in all cases to determine whether averages are significantly
different between treated and untreated groups.
Results
Expression and Purification
The sequence of human CD59 was modified by genetic
engineering to contain a run of 6 histidine residues (the his-
tag), respectively, and transfected into the feline cell line
CrFK [29]. Expression was confirmed after selection by
immunoblots using specific antibodies (Fig. 1, bottom,
samples labelled ‘‘B’’). Purification of CD59his was sub-
sequently performed using an FPLC approach as previ-
ously described [26, 29]. Fractions were collected before
purification (Fig. 1, bottom, samples labelled ‘‘B’’), during
sample loading onto the column and elution. Samples
corresponding to the eluted protein peaks from the FPLC
UV trace (Fig. 1, top, black line) were collected and sub-
jected to ultrafiltration for buffer exchange and concen-
tration. Signals are found in the starting material (Fig. 1,
bottom, samples B) and elution fractions (Fig. 1, bottom,
samples E2–E8) upon increase in the concentration of
imidazole (Fig. 1, top, black dotted line), as expected.
Molecular Painting
Subsequently, we were interested in the recombinant pro-
teins’ ability to perform in MP. For CD59 and MonoGGhis,
MP had been reported previously onto lentiviral and
retroviral particles [26, 29], however not specifically onto
particles produced from the producer cell line PALSG/S
(derived from murine NIH3T3 cells). CD59his could also
be successfully attached to viral particles produced from
these cells (Fig. 2a). This further indicates that the prove-
nance of the viral envelope lipid bilayer does not influence
MP significantly. No signal could be detected when either
no virus, or no CD59his was provided (Fig. 2, panel A,
Fig. 1 Purification of GPI-anchored proteins. The figure shows a
representative result from a series of purification runs. Total cell
extracts were purified using immobilized metal affinity chromatog-
raphy. The upper section of the figure shows the total protein content
of the mobile phase at any given time during the protocol (black line)
and the relative concentration of eluent (dotted line). The vertical
lines separate the fractions taken. In the lower part, fractions taken
from sample loading (L2–L8) and elution (E2–E8) were analysed by
immunoblotting using antibodies directed against CD59 to specifi-
cally detect the purified proteins. Samples taken before application to
the column (B) serve as protein expression control
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bottom, samples ME? and PA-, respectively). Only a
very weak attachment could be observed when the parental
cell line NIH3T3 was used (Fig. 2, panel A, top, sample
NH?). The presence and the amount of virus were con-
trolled by immunoblotting specific for the MLV Gag pro-
teins. All concentrated cell culture supernatants were
collected from comparable amounts of producing cells.
In previous publications, no significant decrease in
infectivity induced by MP was observed, but a rather strong
loss of virus (activity) as a result of the duration of the
process [29]. We could confirm this time-dependent
decrease (Fig. 2a, compare signals in MLV Gag panel in
lanes PA-, PA? and 100 % PA and Fig. 2b, compare
samples 10 %, PA- and PA?). However, additionally we
observed a small but statistically significant drop in
infectivity between mock-painted and CD59-painted sam-
ples (Fig. 2b, compare samples PA- and PA?).
Cellular Response
Before analysing the response of viral particles treated by
MP with complement regulatory protein to complement,
we were looking at cell lines transfected with said com-
plement regulatory proteins, mainly to see if the recombi-
nant proteins would protect from complement in a
heterologous background. Additionally, we were interested
to see whether the cell membranes, giving rise to the viral
envelopes, are sufficiently susceptible to complement
attack in this setting. HeLa, CrFK, PALSG/S and CrFK
cells stably expressing CD59his were subjected to treat-
ment with active and heat-inactivated serum, and their
numbers followed over a period of 24 h post exposure
(Fig. 3). Expression of the complement regulatory factor
CD59 is demonstrated by immunoblotting from cell
extracts of equal total protein amounts (Fig. 3, bottom
panel). HeLa cells endogenously express CD59 and thus
Fig. 2 Overview of Molecular Painting. The graph shows an
overview of the MP procedure necessary for carrying out the
complement protection studies. a MP with CD59his. Signals are
found if GPI-anchored protein and viral particles are present in the
reaction mix (samples labelled PA?), but neither in the absence of
virus (samples labelled ME?) nor in the absence of GPI-anchored
proteins (samples labelled PA-). When concentrated supernatant
from the non-virus-producing parental cell line NIH3T3 was used for
MP, a faint band is visible in the presence of CD59his (sample NH?).
Control samples indicate the signals corresponding to 10 % CD59his
and 100 % virus input (10 % CD59his and 100 % PA, respectively).
B depicts relative infectivity (transduction rates) from MP-treated
samples. Samples containing only medium or concentrated super-
natant from NIH3T3 do not contribute to infectivity (samples ME?
and NH?; for clarity samples ME- and ME- are omitted). Infection
was observed for both viral particle-containing samples PA- and
PA?. A small, but significant drop in infectivity was observed from
PA- to PA? (factors are inset into columns). As a transduction
control, ten percent of untreated virus input was used for infection
(sample 10 %). Results represent average and standard deviation from
two independent experiments. Asterisks indicate statistically signif-
icant differences between groups
Fig. 3 Cellular responses to serum treatment. The bottom section
shows the expression of complement regulatory proteins in the cell
lines HeLa, CrFK, CrFK stably transfected with CD59his and the
virus-producing cell line PALSG/S. The upper section shows the
survival rates of the cell lines after incubation with active human
serum compared to inactivated serum. The ratio of protection between
CrFK cells not expressing/expressing is inset in the columns. Columns
and error bars represent means and standard deviations, respectively.
Means and standard deviations were calculated from at least four
independent experiments. Additional statistical information is sum-
marized in Supplementary Table 1. Asterisks indicate statistically
significant differences between groups (*p\ 0.05; **p\ 0.01)
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could serve as a positive control for complement protec-
tion. The human cell line HeLa indeed showed an
increased growth (CSR[ 100 %) when cultured with
active human serum, most probably due to the availability
of fully active species-specific growth factors in serum.
CrFK and PALSG/S cells were not expressing CD59. Both
cell lines were more susceptible to complement lysis, with
the strongest effect being seen in the cell line used for virus
production (PALSG/S). CrFK cells expressing CD59his
after stable transfection showed an increased resistance to
complement activity (Fig. 3, compare samples CrFK and
CrFK59). When performing statistical analysis of the
results, cell survival rates (CSR) for CrFK cells CD59his
were not statistically significantly different from those
observed for perfectly protected HeLa cells, but quite
decidedly different from effects on PALSG/S cells which
provide the membranes for viral envelopes (see supple-
mentary table 1).
Virus Response
Finally, we were interested to see whether MP of viral par-
ticles could provide protection from the complement activity
of human serum. Virus particles painted with CD59his or
mock-painted were subjected to treatment with either active
or heat-inactivated human serum. Virus samples were then
used for infection of HeLa cells and analysed by flow
cytometry 72 h post infection (for an overview of the
experimental procedure see Fig. 4a). The ratio of viruses that
remained infectious after treatment with active human serum
(compared to treatment with inactivated serum) was
increased for virus paintedwithCD59his (Fig. 4b). AVPFof
1.49 was observed, corresponding to 49 % more virus par-
ticles available for infection, for viruses treated with
CD59his. The VPF indicates to what extent a treatment (i.e.
MPwith CD59his) allows the virus to better withstand serum
complement activity. When a non-complement regulatory
protein—the monomeric GFP variant MonoGGhis—was
used for MP, no such effects were seen (see supplementary
figure 1). VPF is calculated as the ratio of the relative virus
survival compared to a reference (i.e. non-treated). The rel-
ative virus survival is calculated as the percentage of infected
cells (showing green fluorescence) incubated with virus
samples treated with active serum multiplied with 100, then
divided by the percentage of infected cells incubated with
samples treated with inactivated serum.
Discussion
In this study, a different virus-producing cell line was
subjected to MP than previously reported: the murine
NIH3T3-based PALSG/S cell line. When comparing MP
results from these to previously reported MP of virus
derived from human cell lines [29], an interesting effect
was observed. Supernatants derived from the non-virus-
producing cell line NIH3T3 were also amenable to MP (see
Fig. 2, samples NH- and NH?). This is most likely a
result of concentration of membrane vesicles such as
exosomes during preparation. As a consequence, MP may
also be developed for applications on exosomal prepara-
tions. Also, no significant difference in infectivity was
observed between MP- and mock-treated virus preparations
in previous experiments [29]. In this study, we could
identify a small, but statistically significant decrease in
infectivity with CD59his-treated virus as compared to
mock-treated one (see Fig. 2b, samples PA? and PA-).
The different virus-producing cell lines used (HEK293T
based in earlier experiments, NIH3T3 based in this
experiments) may thus have different sensitivities. Alter-
natively, this decrease may depend on the efficiency of
protein insertion, i.e. a certain density of inserted GPI-
anchored proteins may interfere with virus binding and/or
Fig. 4 Viral responses to serum treatment. a The scheme shows an
overview of the experimental procedures leading to the results
presented in the graph in b. b Virus particles derived from PALSG/S
cells subjected to MP with CD59 were incubated with active or
inactivated human serum and finally used to infect HeLa cells. 72 h
post infection, cells were harvested and analysed by flow cytometry.
Columns and error bars represent means and standard deviations,
respectively. Shown are protection factors, showing the relative
increase of virus survival compared to mock-treated virus particles
(numerical values inset in columns). Asterisks indicate statistically
significant differences between groups. Columns and error bars
represent means and standard deviations, respectively. Means and
standard deviations were calculated from three independent experi-
ments. Viral particles were protected better from serum complement
activity after MP with CD59his. c Immunoblots were carried out to
control for successful painting (CD59his signal only visible in the
presence of virus and GPI-anchored protein not in samples containing
no virus or no protein; compare samples PA?, ME? and PA-) and
virus amounts (comparable levels of MLV Gag protein were found in
PA- and PA? samples). IN signifies the 10 % untreated input level
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fusion. Interestingly, expression of CD59his failed in
PALSG/S and the parental NIH3T3 cells, even after repe-
ated attempts using different transfection protocols. This is
unfortunate because viruses harvested from these trans-
fected producer cell lines would have provided an inter-
esting control for determining efficacy of MP when
compared to transfection-based approaches. Also, the
maximum protection that would have been achieved in
these cells by transfection with CD59his would have been
interesting. In general, the reaction of cell lines to human
serum was mostly as expected. HeLa cells, which are of
human origin (expressing CD59), were fully resistant to
human complement. CrFK and PALSG/S (lacking
expression of CD59) demonstrated varying degrees of
complement lysis, with the stronger effects observed in
PALSG/S (Fig. 3, top). This may be due to the fact that
while both cell lines are of non-human origin (feline and
murine, respectively) and will thus carry complement-
stimulating determinants, PALSG/S cells also express viral
antigens, which may lead to a more efficient triggering of
the complement system [39, 41]. CrFK cells expressing
CD59his showed an intermediate response (i.e. partial
protection, protection factor of 1.64 compared to non-ex-
pressing) to active serum (see Fig. 3). This may indicate
the need for cooperation between two or more regulatory
factors to confer full protection. Alternatively, expression
may be too low or protein functions reduced as a result of
introduction of the his-tags. Taken together, these results
suggested that virus produced from PALSG/S cells is
susceptible to complement activity, even in the absence of
specific antibodies, and furthermore that recombinant
CD59his is able to provide at least partial protection from
the complement system. Both conclusions are important
prerequisites for determining effects of MP with comple-
ment regulatory factors on viral vectors. Upon modification
by MP, virus samples were subjected to active human
serum and then used to infect HeLa cells (see Fig. 4). We
were interested to see if modified virus would be more
competent in withstanding complement attacks, indicated
by the ratio of infected cells after treatment with active vs.
inactive serum, i.e. the VPF (see Fig. 4). Indeed, viral
particles modified with CD59his were better able to with-
stand complement activity than mock-treated virus parti-
cles or particles modified with the control GFP-based GPI-
anchored protein, MonoGGhis (see supplementary fig-
ure 1). The VPF, i.e. the multiple of protection introduced
by CD59 modification in comparison to mock-treated viral
particles, achieved by MP seems low, with the CD59his
modification giving a virus protection factor of 1.49 (see
Fig. 4). However, in practical terms, this means that 49 %
more virus is available for productive infection. This may
very well prove relevant for use in gene therapy applica-
tions. Several reasons will contribute to the protection
being only partial. Introduction of GPI-anchored protein
may negatively affect infectivity by default (see Fig. 2,
samples PA- and PA?). When correcting for this effect,
nearly 100 % more virus is available for infection. Also
introducing MonoGGhis by MP is reducing serum protec-
tion. Reduction levels were strikingly similar (0.78 for
general infectivity reduction by MP in the absence of active
serum and 0.82 for MP with MonoGGhis in the presence of
active serum). This may indicate that the reduction seen
upon MP with MonoGGhis is more likely an effect of loss
of infectivity by GPI incorporation rather than increased
stimulation of the complement system by MonoGGhis. In
the physiological situation in vivo, more than one regula-
tory protein is interfering with complement proteins to
limit their activity. We tried to mimic this situation by
double MP with CD55 (also termed decay accelerating
factor, another GPI-anchored regulator of complement
activity) and CD59. However, MP with CD55 yielded very
little modification, most likely as a result of competition for
available membrane space on the viral envelope. When
comparing the protection achieved in cells and virus
preparation, the protection factors are similar, i.e. 1.64 for
cells (see Fig. 3) and 1.49 (corrected 1.91) for virus (see
Fig. 4). This suggests that the partial protection is rather a
result of the protein function than the MP process, i.e.
defective or incomplete GPI processing may be responsible
for the small protection factor, as well as mis-folding at the
protein level of the CD59his molecule. On a more general
level, complement activity in the circumstances used in this
study will be mostly triggered by the classical pathway in
an immune complex independent manner [23, 24] since all
complement assays have been performed in the absence of
antibodies. Also the lectin pathway may be triggered by the
presentation of unusual carbohydrates on the murine- and
feline-derived envelope structures [23, 24]. This suggests
that viral vectors produced in human cells may also be
susceptible to inactivation by the complement system, if
insufficient amounts of complement regulatory proteins are
present without modification by MP.
GPI-anchored proteins are notoriously difficult to work
with: usually expression levels are low, even when using
strong promoters for driving expression. The low abun-
dance mostly arises from the limitation of the GPI anchor
biosynthesis pathway of cells in general. Additionally, the
strong inherent amphiphilic nature of the GPI anchoring
may promote aggregation events or the formation of
pseudo-micelles, which could in turn contribute to poor
performance in affinity purification. As a result, purity is
poor (approximately 1 % as measured by his-tag ELISA,
data not shown).
In this study, we could demonstrate that modification of
retroviral vector particles with a regulator of the comple-
ment system using MP leaves them less susceptible to
486 Mol Biotechnol (2016) 58:480–488
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complement attack. On a more general note, this provides
further evidence for the usefulness of MP in a range of
biomedical applications, from labelling of virus particles
for research purposes [26] and vaccination strategies using
VLPs [32, 34] to fine-tuning vector properties for gene
therapy applications [25, 27, 28, 30].
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